Duchenne muscular dystrophy is a severe X chromosome-linked, muscle-wasting disease caused by lack of the protein dystrophin. The exact function of dystrophin rem to be determined. However, analysis of its interaction with a large oligomeric protein complex at the sarcolemma and the identicaton of a structurally related protein, utrophin, is leading to the characterization ofcandidate genes for other neuromusular disorders.
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Duchenne muscular dystrophy (DMD) is the most common muscular dystrophy, affecting 1 in 3,300 boys. It leads to severe muscle wasting and eventual death in the late teens or early twenties due to cardiac or respiratory failure. Becker muscular dystrophy (BMD) is an allelic disorder that is less common (1 in 30,000 boys) and less severe, with a later onset and much longer survival rate. Both disorders are caused by mutations within the dystrophin gene, resulting in a lack of dystrophin (usually DMD) or the expression ofmutant forms ofdystrophin (usually BMD) . Dystrophin is a member of a growing family of related proteins, including the autosomally encoded protein utrophin. There have been several recent reviews covering the structure and potential functions of dystrophin and utrophin, and the reader is referred to these for detailed references (1) (2) (3) . This review focuses on the proteins with which dystrophin and utrophin interact.
Dystrphin and Utrophin Genes:
A Brief Overview
The dystrophin gene is the largest gene so far identified in humans, covering >2.5 megabases and containing 79 exons. The unusually high mutation rate at the DMD locus may, in part, be accounted forby the large size of the gene. The corresponding 14-kb dystrophin mRNA is expressed predominantly in skeletal, cardiac, and smooth muscle; lower levels appear in brain. Transcription of dystrophin in different tissues is regulated from either the brain promoter (predominantly active in neuronal cells) or muscle promoter (differentiated myogenic cells and primary glial cells) giving rise to different first exons. A third promoterbetween the muscle promoter and the second exon of dystrophin regulates expression in cerebellar Purkinje neurons. Alternatively spliced isoforms originating from the carboxylterminal coding region ofdystrophin have also been described. The significance of these isoforms at the RNA and protein level has not been elucidated.
Dystrophin is a 427-kDa protein localized to the cytoplasmic face of the sarcolemma, enriched at myotendinous junctions and the postsynaptic membrane of the neuromuscular junction (NMJ) . Dystrophin colocalizes with f3-spectrin and vinculin in three distinct domains at the sarcolemma (overlaying both I bands and M lines), lying as an array ofthick bands localizing at the sites of attachment of the sarcomeres to the muscle plasma membrane. The carboxylterminal region of dystrophin is bound to the protoplasmic half of the plasmalemma. Thus dystrophin forms an intricate part of the muscle cytoskeleton and may function to link the normal contractile apparatus to the sarcolemma. In the brain, dystrophin is also localized at the postsynaptic regions of some neurons.
The (5) . Apo-dystrophin-1 is first detected at 11.5 days in the ventral midline of the hindbrain. Later expression of apo-dystrophin-1 occurs in central nervous system glia, teeth primordia, and in the liver. Apo-dystrophin-2 appears to be a rare transcript during development but is detected at low levels in the region of the caudate putamen in newborn mouse brain (5) .
Utrophin is a 395-kDa protein encoded by a large (1 Mb) multi-exonic gene located on chromosome 6q24 (6) . The (10, 11) and Yoshida and Ozawa (12) . Tight association of these proteins was demonstrated by copurification from rabbit muscle membranes, cosedimentation on sucrose density centrifugation, immunoprecipitation, colocalization to the sarcolemma, and protein crosslinking experiments. Table 1 details the names of the dystrophin-associated glycoproteins (DAGs) and dystrophin-associated proteins (DAPs), their molecular weights, and location within muscle. Fig. 1 depicts diagrammatically the location of the DAP complex and other associated proteins localized to the sarcolemma (described later).
The 43DAG (A3) and 156DAG are derived from a single 97-kDa precursor protein translated from a 3.8-kb transcript (15) . The 43-156DAG transcript is expressed not only in skeletal, cardiac, and smooth muscle but also in other tissuesnamely, brain, lung, liver, and kidney. Cleavage and posttranslational modification of the carboxyl-terminal portion gives rise to the 43DAG. The 43DAG has sites for glycosylation, a transmembrane domain, and a cytoplasmic tail (15) . On acrylamide gels, the 43DAG (A3) is a component of a doublet, A3a and A3b (12, 16) . The 43DAG is the same as A3a, as determined by peptide sequence analysis of the purified gel band. A3b is distinct from A3a, as it has a different proteolytic cleavage pattern (14) and is unable to bind dystrophin (16) . The 56-kDa amino-terminal core protein once glycosylated at many of the potential O-glycosylation sites gives rise to the fully processed 156DAG (15) . Recently a protein of 120 kDa called laminin-binding protein 120 (LBP120) has been isolated from the brain and shown to have peptide sequences identical to 156DAG (17) . The size difference between the two proteins is probably due to different glycosylation. Because of their posttranslational modification and their interaction with dystrophin, these proteins have now been renamed a-(156DAG) and (3-(43DAG) dystroglycan (15) .
The 59-kDa membrane-bound protein named 59DAP or Al has been independently cloned from a number of species, and recent evidence shows this is a family of related genes, some of which bind to dystrophin. They have been renamed syntrophins (syntrophos from Greek, meaning companion). These constitute an increasingly complex family of proteins and are discussed later.
The 50-kDa glycoprotein (5ODAG/A2) has been cloned from rabbit skeletal muscle (18) . The protein consists of a short signal sequence, one transmembrane domain, and two potential sites for N-linked glycosylation. In contrast to dystroglycan, expression of the SODAG is specific to skeletal, cardiac, and smooth muscle (18, 19) . This protein has been renamed adhalin (from the Arabic word for muscle, adhal).
At present the cloning of the 35DAG (A4) and 25DAP (AS) has not been reported, so their potential functions have yet to be elucidated. However, 35DAG expression appears restricted to striated muscle (19) . A 94-kDa protein, AO, which also copurifies with the DAP complex, has been identified (12) . Circumstantial evidence suggests that AO may be related to the Torpedo 87-kDa postsynaptic protein (discussed later).
Recently, the purified DAP complex purified from rabbit skeletal muscle has been divided into three subcomplexes based upon detergent solubilization using 1-octyl f-D-glucoside (14) . The groups consisted of a-and f-dystroglycan (dystroglycan complex), adhalin, 35DAG and A3b (sarcoglycan complex), and a complex of dystrophin, syntrophin, and AO. The restricted expression patterns of adhalin and 35DAG suggests that the sarcoglycan complex may be specific to striated muscle.
Emergence of the Syntrophin Family of Proteins
In 1987, Froehner et al. (20) described a 58-kDa protein that was associated with the cytoplasmic side of the AChRs in Torpedo electroplaques. Analysis ofadult rat muscle using a monoclonal antibody raised against this 58-kDa protein strongly stained the NMJ but also, to a lesser extent, stained the sarcolemma (20) . In 1990, initial analysis of rabbit 59DAP/A1 by one-dimensional PAGE demonstrated that the protein separated as a triplet of bands thought to be a result of differing posttranslational modifications or possi- (12, 21) . Recent analysis of 59DAP/A1 by two-dimensional gel electrophoresis resolved the proteins into two major groups-namely, the (3-Al group which was larger (64 kDa) and more basic than the a-Al group (60 kDa) (16) . In retrospect, the 58-kDa Torpedo protein and the 59DAP/Al proteins all originate from the same family of genes, the syntrophins.
Syntrophin genes of Torpedo, mouse, rabbit, and human have recently been cloned. In the mouse, two related proteins were shown to be derived from different genes. These were named syntrophin-l and syntrophin-2 (22) . Expression of the 2.2-kb mouse syntrophin-1 transcript was highest in striated muscle, lower levels were found in brain, and expression was barely detectable in the other tissues tested. There are multiple syntrophin-2 transcripts (10 kb, 5.0 kb, and 2.2 kb) expressed in all tissues tested with lowest levels in skeletal muscle. However, the relative expression of each of these transcripts varies from tissue to tissue. For example, the 2.2-kb transcript was predominant in testes, the 5.0-kb transcript was predominant in lung, and the 10.0-kb transcript was predominant in brain (22) . An antibody against Torpedo syntrophin (20) reacts with both of the mouse syntrophin species (22) . Recently, using peptide antibodies specific to mouse syntrophin-1 or mouse syntrophin-2, syntrophin-1 was localized to rat muscle sarcolemma and AChRs, whereas syntrophin-2 was localized only at the AChRs (23) .
The cDNA coding for 59-lDAP has been cloned from rabbit skeletal muscle and shown to have 94% amino acid identity to mouse syntrophin-1, suggesting that this is the rabbit homolog of syntrophin-1 (24). The 2.4-kb transcript has an almost identical expression pattern as mouse syntrophin-1. An antibody to rabbit syntrophin-1 detects only the lowest band of the 59DAP/Al triplet of proteins seen by one-dimensional PAGE (24) .
Finally, a third syntrophin gene has been identified from human tissue (25) . Purification and partial peptide sequencing of the human a-and 3-Al proteins (separated by two-dimensional PAGE) confirmed that a-Al is the human homolog of mouse syntrophin-1. A cDNA containing the (3Al peptide sequences was isolated encoding a protein of 58.7 kDa, which is related to but distinct from mouse syntrophin-l and -2. There appear to be multiple transcripts (7.8, 7.2, 6 .0, 3.8, and 2.4 kb) expressed from the (3-Al gene, which are detected in various amounts in all tissues tested. A search of sequence data bases using the human ,(Al cDNA sequence identified a skeletal muscle-expressed sequence tag (EST25263) that had strong homology to mouse syntrophin-2 (25) .
It has been agreed by the laboratories that have adopted the syntrophin nomenclature to rename the syntrophins on the basis of their amino acid similarity and their acidic (a, pI z6.7) or basic ((3, pI -9+) nature (23) . Thus mouse syntrophin-1, rabbit 59-lDAP, and Torpedo syntrophin are now named al-syntrophins. Mouse syntrophin-2 and the human gene encoding the EST25263 fragment are ,32-syntrophins. Finally the human (3-Al is a member of the (31-syntrophins. Table 2 shows the amino acid similarity between the cloned syntrophin species. The overall amino acid similarity of Torpedo syntrophin is in the order of 50%o when compared with either the al-syntrophins or the (-syntrophins. It will be of interest to see if Torpedo has only one syntrophin, suggesting that the other syntrophin genes have evolved from a single ancestor.
Association of Other Proteins with Muscle DAPs
As the name DAP suggests, dystrophin was the first protein shown to interact .mc;view: Tinsley et al.
Proc. Natl. Acad. Sci. USA 91 (1994) suggest- ing that this region is unable to bind directly but may be important for maintaining the correct conformational binding structure (13) . Immunogold labeling of muscle localized P-dystroglycan to the plasma membrane at the same site as the dystrophin carboxyl terminus (27) .
The latter half of the carboxyl terminus of dystrophin has a leucine-zipper motif (1), which may play a role in the binding of syntrophin and/or the 87-kDa protein (13) . One interpretation of the literature (although not formerly proven) is that this 87-kDa protein may be the same as that labeled AO (12, 13) , which in turn may be the same as the 87-kDa cytoplasmic peripheral membrane protein identified in Torpedo (28) . This is a good candidate because in Torpedo, 87-kDa protein expression is restricted to the electric organ, brain, and skeletal muscle (28) and, most importantly, is copurified as a complex containing dystrophin and syntrophin (29) . Sequence analysis of the 87-kDa protein reveals homology to the carboxylterminal region of dystrophin, including the putative leucine zipper (1, 29 Laminins are a family of basementmembrane glycoproteins. The a-dystroglycan binds to laminin and merosin (Mlaminin) situated in the extracellular matrix (33) . Laminin-Sepharose, as well as purifying a-dystroglycan, also copurified all the other members of the DAP complex (33) . The binding of a-dystroglycan to laniinin is specific-probably at one of the heparin-binding domains, with no demonstrable binding of other extracellular matrix components such as fibronectin, collagen I, collagen IV, entactin, or heparin sulfate proteoglycan (33) . The major effect ofbinding laminin to a-dystroglycan would be to link the sarcolemma to the extracellular matrix, potentially providing an additional strengthening mechanism to allow the muscle fibers to withstand the enormous stresses of contraction and stretch. Laminin-Sepharose also bound a-dystroglycan from nonmuscle tissues. However, the other members of the muscle DAP complex were lacking, suggesting they do not exist in nonmuscle tissue, that they are antigenically dissimilar, or that they simply do not bind together as tightly as the muscle complex (33) .
Agrin is an extracellular matrix protein that appears to be able to direct the accumulation of AChRs at developing and regenerating NMJs. Independent evidence from three different groups suggests that a-dystroglycan is an agrin receptor (34-36). Bowe (36) demonstrated that a-dystroglycan could bind agrin in vitro by different methods and that the binding was calcium and heparin dependent (35) . Analysis of mouse C2 myotubes by immunofluorescence demonstrated that agrin, utrophin, and a-dystroglycan were concentrated at the AChR clusters (35, 36) .
Thus, in muscle the DAP complex appears to have two very important roles. regions between the motor neuron and muscle (Fig. 2) .
Association of Other Proteins with Nonmuscle DAPs
It is very probable that utrophin also binds to a related complex in nondystrophin-expressing cell types. The presence of a-dystroglycan expression in nonmuscle tissues (15) and the identification of a smaller (120 kDa) brain a-dystroglycan isoform (17) suggests that this protein may have other binding partners. In mouse, f32-syntrophin expression occurs in all tissues examined (22, 24) , mimicking utrophin expression and suggesting a higher specificity for binding utrophin. Specific antibodies only detect 82-syntrophin in rat kidney and not in alsyntrophin (23) . In peripheral nerves found among muscle fibers ofnormal and DMD muscle, utrophin and f-dystroglycan are clearly detected, but no 50DAG is detected (37) . The (21) and Suzuki et al. (13) , this would be the minimum complex required to link laminin (in the extracellular matrix) to actin via utrophin. As actin and laminin isoforms are found in all cells, this could provide a scaffold to link stably these intra-and extracellular proteins and thus be a mechanism to give rigidity to all cells.
Syntrophin preparations from various rat tissues copurify a protein of 71 kDa, which reacted with an antibody raised against the unique amino terminus of apodystrophin-1 (Dp71) (38) .
Potential for Disease Caused by Defects in the DAPs or Associated Proteins
In DMD the levels of all the DAPs are reduced (11, 37, 39) (40) . In some cases these patients express a truncated form of dystrophin that appears to localize correctly to the sarcolemma-presumably due to an intact amino-terminal actin-binding domain (41) . Dystrophin mutations originating within the actinbinding domain giving rise to an in-frame fusion protein result in variable phenotypes, suggesting that the presence of a functional dystrophin carboxyl terminus is capable of stabilizing a proportion of the DAP complexes (42) .
In BMD there is a general mild reduction in the DAPs-probably because most mutations involve in-frame deletions ofthe rod domain, leaving the actinbinding and DAP-binding regions intact (43) . These truncated forms of dystrophin must be partially effective in both organizing the DAP complex into the correct conformation and linking with the cytoskeletal actin. Interestingly, symptomatic DMD carriers have significantly reduced DAPs in dystrophin-deficient regenerating fibers, whereas they were expressed at normal levels in the normal dystrophin-positive fibers (44, 45) .
All of these results have led to the notion that dystrophin localizes or stabilizes the DAP complex. Without dystrophin the complex is unable to organize properly, and consequently the linkage between the extracellular matrix and the subsarcolemma is disrupted; this eventually leads either to the gross muscle necrosis seen in DMD or to the less severe phenotype in BMD, where expression of a partially functional dystrophin results in a partial retention of the DAPs.
Further analysis of autosomal muscular dystrophies has strengthened this hypothesis. Deficiency in only adhalin (50DAG) is observed in patients suffering from severe childhood autosomal-recessive muscular dystrophy (SCARMD) (46) (47) (48) . SCARMD has been mapped to 13q12 by linkage analysis of 16 Tunisian pedigrees (49, 50 DAPs is seen, particularly of (dystroglycan (43DAG), in some muscle fibers (54, 55) . However abnormal ,B-dystroglycan staining can only be a secondary effect, as the genetic defect for Fukuyama-type muscular dystrophy has been mapped to 9q31-33, whereas the dystroglycan gene is located at 3p21 (56) ( Table  3 ). In both these human diseases, dystrophin expression is normal, but symptoms are akin to severe BMD.
Decreased laniinin expression has been demonstrated in a number of muscular dystrophies (57) . Recently, analysis ofthe severely dystrophic, autosomally recessive dy/dy mouse demonstrated a complete lack of merosin and vastly reduced levels of merosin mRNA in skeletal muscle, cardiac muscle, and peripheral nerve. The heterozygous dy/+ (nondystrophic) had normal levels of merosin. Ultrastructural analysis of the basement membrane showed it was unusually fragmented or even absent in the dystrophic mice. The human chromosomal localization of merosin is 6q22-23. Recently merosinnegative congenital muscular dystrophy has been mapped to 6q2 (58) . This region is syntenic with mouse chromosome 10 at the position where the dy locus maps. These results suggest that a defect in merosin expression may be directly responsible for the muscle necrosis and resulting muscular dystrophy seen in these mice (59) (60) (61) . Two autosomal recessive mouse mutants, ducky and tippy, map to chromosome 9. Both mouse mutants have problems walking, and tip/tip mice also have neurological defects. This region is syntenic with human 3p21-pter, which contains the dystroglycan gene, suggesting that mutations in this gene may cause muscle and/or neurological disorders (56) .
The above results demonstrate the importance of the DAP complex in muscle function and integrity and suggest that any deficiency of this complex either directly, or indirectly, results in muscular dystrophy and possibly other neurological disorders (Table 3) . At present the genomic localizations of the other members of the DAPs are not known; their role as candidate genes has not yet been fully explored. Given the wide diversity of cell types in which members of the DAP complex are expressed, it is also possible that other nonmuscle disorders will be caused by aberrant expression of this complex family of interacting membrane proteins.
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